Bausch + Lomb to Advance Eye Disease Treatment Post FDA Meeting

Bausch + Lomb announced plans to move forward with its eye disease treatment, BL1243 (tonabersat), following a constructive meeting with the Food and Drug Administration that provided clarity on its development path.